← Back to home
Trust Score: 30%

Trust Score calculated by AI analyzing study rigor, sample size (n), and the scientific source impact factor.

9/30/2026

Imeglimin Reduces Muscle Atrophy in Metabolic Dysfunction-Associated Steatohepatitis Models

Summary

“The study examined imeglimin's impact on MASH‑associated muscle atrophy, but the abstract does not report the outcome.”

AC
Adrian CastroEditorially reviewed

Adrian Castro created Biohacker Age to have a place to closely follow longevity and biological optimization research without relying on sensationalist headlines. Content is produced with AI assistance from scientific literature and is editorially reviewed before publishing.

About our methodology →

The Finding


Osaki et al. (Department of Gastroenterology) performed an experimental investigation using metabolic dysfunction‑associated steatohepatitis (MASH) models to assess whether imeglimin attenuates muscle atrophy; the abstract does not disclose sample size or quantitative outcomes.

How They Got There


The study employed a preclinical design in which animals (or cell cultures) with MASH were treated with imeglimin and compared to untreated controls. Primary endpoints mentioned in the study rationale include skeletal‑muscle fiber cross‑sectional area, mitochondrial respiration capacity, and inflammatory cytokine levels such as TNF‑α and IL‑6. Because the abstract lacks detailed methodology, the exact assays (e.g., respirometry, histology, ELISA) remain unspecified.

The Mechanism: What Happens Biologically


Imeglimin is classified as a mitochondrial modulator. In vitro work suggests it enhances complex I activity, promotes NAD⁺ regeneration, and activates AMPK signaling, thereby improving oxidative phosphorylation. Parallel reductions in NF‑κB‑driven transcription can lower TNF‑α and IL‑6 production, creating a metabolic environment less prone to catabolic muscle loss.

Study Limitations



  • Absence of reported sample size prevents assessment of statistical power.

  • Results are confined to MASH models; translation to human physiology is untested.

  • Lack of detailed methodological description limits reproducibility.

Practical Application


It is too early to apply this to a personal protocol. Human trials, clear dosing regimens, and replication in larger cohorts are needed before imeglimin can be recommended for performance‑oriented muscle preservation.



Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.

Legal Notice

Medical Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or supplementation.

Science in your inbox

The most relevant studies of the week, curated and analyzed.

No spam. Unsubscribe anytime.